Reduced von Willebrand factor survival in type Vicenza von Willebrand disease

Blood

Volumn 99, Issue 1, 2002, Pages 180-184

  Casonato, Alessandra ^a   Pontara, Elena ^a   Sartorello, Francesca ^a   Cattini, Maria Grazia ^a   Sartori, Maria Teresa ^a   Padrini, Roberto ^a   Girolami, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; GLYCOPROTEIN IB; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING TENDENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC ANALYSIS; HALF LIFE TIME; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

EID: 0036095699     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.180     Document Type: Article

References (27)

1. Von Willebrand factor and von Willebrand disease
2. A revised classification of von Willebrand disease
3. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand disease
4. Von Willebrand disease type B: A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein lb
5. Variant von Willebrand's disease: Characterization of two sub-types by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets
6. Von Willebrand disease "Vicenza" with larger-than normal (supranormal) von Willebrand factor multimers
7. Von Willebrand disease type 2M "Vicenza" in Italian and German patients: Identification of the first candidate mutation (G3864A; R1205H) in 8 families
8. New families with von Willebrand disease type 2M (Vicenza)
9. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets
10. In vivo experiments indicate that relatively high platelet deposition in von Willebrand disease "Vicenza" is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma
11. Molecular mechanism and classification of von Willebrand factor disease
12. The genetic defect of type I von Willebrand disease "Vicenza" is linked to the von Willebrand factor gene
13. An additional unique candidate mutation (G2470A; M740) in the original families with von Willebrand disease type 2M Vicenza and the G3864A (R1205H) mutation
14. A new variant of von Willebrand's disease (type I Padua): Doublet-organized plasma von Willebrand oligomers in the presence of all size multimers
15. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction and the presence of all von Willebrand factor multimers in plasma
16. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content
17. The evaluation of factor VIII antigen by means of a simple slide test
18. A new congenital haemorrhagic condition due to the presence of abnormal factor X (factor X Friuli): Study of a large kindred
19. Abnormal collagen binding activity of 2A von Willebrand factor: Evidence that the defects depends only on the lack of large multimers
20. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy in von Willebrand's disease subtypes
21. Mutations causing dominant type 1 von Willebrand disease with high penetrance
22. The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: A study of 34 patients with various subtypes of type I von Willebrand disease
23. Von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy
24. Which assay is the most suitable to investigate von Willebrand factor functional activity?
25. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIA von Willebrand's disease: Studies with protease inhibitors
26. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor